Beginning at the moment, Dexcom G7 steady glucose monitor (CGM) customers will be capable to monitor their real-time blood sugar information straight from an Apple Watch.
In response to Dexcom’s press launch, the Direct to Apple Watch function was some of the requested by customers. As soon as paired to the Apple Watch, the G7 will use its personal devoted Bluetooth connection to ship each glucose readings and customized alerts to the wrist. Which means, you don’t should whip out your telephone if you wish to view your information, nor does your telephone should be in your particular person. As an example, G7 customers will nonetheless be capable to get real-time information whereas on a phone-free run / stroll or in case your telephone is charging in a unique room. Beforehand, the G7’s Apple Watch app allowed you to have a watchface complication, however there was a three-hour delay with synced information.
That is extra of a secondary option to view information and obtain alerts, not a substitute to your smartphone or Dexcom receiver. You continue to want a appropriate iPhone to initially arrange the G7 CGM and pair it with the Apple Watch. Sharing information with household and mates additionally requires your telephone to be inside 20 ft of vary. You’ll additionally want your telephone in order for you a extra holistic view of your blood glucose information alongside different metrics (e.g., exercise, menstrual cycles, sleep, and so forth.) within the Apple Well being app.
At launch, the Direct to Apple Watch function will probably be out there within the US, UK, and Eire. The function will roll out to further markets later this month, although Dexcom didn’t specify precisely which. Of us within the function ought to replace the Dexcom G7 app to model 2.1 and can want no less than an Apple Watch Collection 6 operating watchOS 10 or later. They need to even have an iPhone operating iOS 17 or later.
It’s necessary to notice that this function is extra a step in making current CGMs extra handy to make use of, fairly than making smartwatches a standalone, non-invasive blood glucose monitoring device. (Whereas many firms are actively investing that tech, it’s nonetheless unlikely we’ll see it anytime quickly.) Alongside that vein, Dexcom additionally just lately introduced it obtained FDA clearance for the Stelo CGM, an over-the-counter machine geared towards non-insulin dependent, Sort 2 diabetes sufferers. The Stelo, which was launched at CES 2024, is anticipated to be out there later this summer time.